Process Development chosen by Karolinska Development AB as preferred supplier for the development of pharmaceutical products and CMC activitiesWe are proud to announce that SP Process Development has been selected as a preferred supplier for pharmaceutical development and CMC activities by Karolinska Development AB, who manages one of the largest portfolios of life science companies in Europe.
Process Development has been selected following a thorough selection procedure in competition with the top level providers of CMC development from all over Europe.
By partnering with Karolinska Development, SP Process Development, establishes itself as a recognized collaborator, for a high quality and integrated state of the art pharmaceutical development of new drug products.
The agreement gives the Karolinska Development affiliates access to SP Process Development’s support in pharmaceutical development of drug substance and drug product to propel smooth transition from the laboratory phase to the clinic and finished product
For more information, please contact:
Nicolaas Schipper, +46 10 516 65 06, firstname.lastname@example.org.
About Karolinska Development
Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into differentiated products that can be partnered. The business model is to: SELECT the most commercially attractive medical innovations that can potentially satisfy unmet medical needs; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading universities, delivers a continuous flow of innovations. Karolinska Development is listed on NASDAQ OMX (KDEV).
For more information, please visit: www.karolinskadevelopment.com.